Torner Núria, Martínez Ana, Basile Luca, Marcos M Angeles, Antón Andrés, Mar Mosquera M, Isanta Ricard, Cabezas Carmen, Jané Mireia, Domínguez Angela, Program Of Catalonia The Pidirac Sentinel Surveillance
a Public Health Agency of Catalonia; Department of Health; Generalitat of Catalonia; Barcelona, Spain.
Hum Vaccin Immunother. 2015;11(1):225-30. doi: 10.4161/hv.36155. Epub 2014 Nov 1.
Influenza vaccination aims at reducing the incidence of serious disease, complications and death among those with the most risk of severe influenza disease. Influenza vaccine effectiveness (VE) through sentinel surveillance data from the PIDIRAC program (Daily Acute Respiratory Infection Surveillance of Catalonia) during 2010-2011, 2011-2012, and 2012-2013 influenza seasons, with three different predominant circulating influenza virus (IV) types [A(H1N1)pdm09, A(H3N2) and B, respectively] was assessed. The total number of sentinel samples with known vaccination background collected during the study period was 3173, 14.7% of which had received the corresponding seasonal influenza vaccine. 1117 samples (35.2%) were positive for IV. A retrospective negative case control design was used to assess vaccine effectiveness (VE) for the entire period and for each epidemic influenza season. An overall VE of 58.1% (95% CI:46.8-67) was obtained. Differences in VE according to epidemic season were observed, being highest for the 2012-2013 season with predominance of IV type B (69.7% ;95% CI:51.5-81) and for the 2010-2011 season, with predominance of the A(H1N1)pdm09 influenza virus strain (67.2% ;95%CI:49.5-78.8) and lowest for the 2011-2012 season with A(H3N2) subtype predominance (34.2% ;95%CI:4.5-54.6). Influenza vaccination prevents a substantial number of influenza-associated illnesses. Although vaccines with increased effectiveness are needed and the search for a universal vaccine that is not subject to genetic modifications might increase VE, nowadays only the efforts to increase vaccination rates of high-risk population and healthcare personnel let reduce the burden of influenza and its complications.
流感疫苗接种旨在降低患严重流感疾病风险最高人群中严重疾病、并发症和死亡的发生率。通过2010 - 2011年、2011 - 2012年和2012 - 2013年流感季节来自PIDIRAC项目（加泰罗尼亚每日急性呼吸道感染监测）的哨点监测数据，评估了流感疫苗效力（VE），该项目涉及三种不同的主要流行流感病毒（IV）类型[分别为A(H1N1)pdm09、A(H3N2)和B型]。研究期间收集的已知接种背景的哨点样本总数为3173份，其中14.7%接种了相应的季节性流感疫苗。1117份样本（35.2%）IV检测呈阳性。采用回顾性阴性病例对照设计评估整个时期及每个流行流感季节的疫苗效力（VE）。总体VE为58.1%（95%CI：46.8 - 67）。观察到不同流行季节的VE存在差异，2012 - 2013年B型IV为主的季节最高（69.7%；95%CI：51.5 - 81），2010 - 2011年A(H1N1)pdm09流感病毒株为主的季节次之（67.2%；95%CI：49.5 - 78.8），2011 - 2012年A(H3N2)亚型为主的季节最低（34.2%；95%CI：4.5 - 54.6）。流感疫苗接种可预防大量与流感相关的疾病。尽管需要效力更高的疫苗，并且寻找不受基因变异影响的通用疫苗可能会提高VE，但目前只有努力提高高危人群和医护人员的接种率才能减轻流感及其并发症的负担。
